BioSpace News Archive

With data from the Phase III trial of donanemab expected in Q2, Eli Lilly presented the first clinical results from its next anti-amyloid antibody, remternetug, at AD/PD 2023.

Gossamer Bio announced Monday that it is discontinuing the development of its lymphoma candidate, GB5121, following two patient deaths in the Phase Ib/II STAR-CNS study.

The Inflation Reduction Act contains provisions designed to influence drug prices. These policies might affect drug development and the prioritization of new drugs.

The FDA has approved the combination regimen of Merck’s Keytruda and Seagen and Astellas’ Padcev for the first-line treatment of locally advanced or metastatic urothelial carcinoma.

With an inaugural $350 million fund, Cure Ventures launched Tuesday to support early-stage companies with cutting-edge curative technologies and help them de-risk their science

The money saved on canceling the existing studies is intended to fund the advancement of two other oncology pipeline assets.

The Centers for Medicare and Medicaid Services released details about the patient registry it will require physicians to use to prescribe Leqembi, should it be approved by the FDA.

Two studies, published in The Lancet and The Lancet Haematology, evaluating the efficacy and safety of fitusiran, an investigational siRNA therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B, reinforce the potential of this investigational therapy to transform the current standard of care and address unmet needs for all types of hemophilia, regardless of inhibitor status.

OKYO Pharma Limited announces that it has applied to the UK Financial Conduct Authority and London Stock Exchange plc to effect a cancellation of its ordinary shares of no par value each from listing on the standard segment of the FCA’s Official List and trading on the main market for listed securities of the LSE .

Biovica International Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership agreement with the Italian company, IT Health Fusion, for the commercialization of the DiviTum® TKa assay in Italy.